Drugs of abuse screening benefits from LoGiCal® reference materials
Publication date: 29 October 2012
Author: kdm communications limited
Tagged with: Elin Widing, Unilabs AB
Unilabs AB in Eskilstuna, Sweden, is taking advantage of LGC Standards’ LoGiCal reference materials to perform clinical analyses and screen for drugs of abuse, as chemist Elin Widing explained: “Unilabs is a privately owned clinical laboratory that analyses company healthcare and workplace samples, as well as samples from drug abuse centres. Samples are received from across Sweden and screened either qualitatively or semi-quantitatively using immunological assays, followed by quantitative LC-MSMS or GC-MS analysis for verification. Ready-to-use LoGiCal solutions are ideal for our purposes; it is so much simpler than weighing powders for in¬house preparation of reference materials.”
Elin Widing, chemist at Unilabs AB in Eskilstuna, Sweden.
“We evaluated LoGiCal solutions of tetrahydrocannabinol (THC), zopiclone and alpha-hydroxyalprazolam, including deuterium-labelled alpha-hydroxyalprazolam as an internal standard for quantitative mass spectrometry analysis. Analyses were run in parallel with assays that were using our existing reference materials, and the results were comparable. LoGiCal reference materials are very good quality and competitively priced and, since the initial product evaluation, we have also ordered tramadol and its metabolites for our laboratory. In the future, as we purchase more reference materials, we intend to use LoGiCal solutions whenever they are available.”
To learn more about the LoGiCal product range, visit www.logical-standards.com
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Novartis wins GBCHealth Business Action on Health Award for social ventures initiative (17 May 2013)
- Could a ‘super computer’ help improve epilepsy care? Yes, it’s elementary my dear WATSON (16 May 2013)
- Promising new data demonstrate that a novel pain therapy system manages patients with chronic neuropathic pain (16 May 2013)
- Roche’s obinutuzumab significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer (16 May 2013)
- AstraZeneca issues update on accelerated oncology pipeline in advance of 2013 ASCO Annual Meeting (16 May 2013)
Mass Spectrometry: In-depth focus
This free to view Mass Spectrometry in-depth focus features articles from experts at University of British Columbia and University of Colorado Denver.
Stem Cells: In-depth focus
This free to view Stem Cells in-depth focus features articles from experts at Max Planck Institute for Molecular Genetics, Heinrich Heine University and Newcastle University.
Company directory
ABB Analytical Measurements | Analytik Jena AG | Aptalis Pharmaceutical Technologies | ASM - Aerosl-Service AG | Azbil BioVigilant, Inc. | B&W Tek, Inc. | Bio-Optronics, Inc. | bioMérieux | BioTrends – Archilex SA | BMG LABTECH GmbH | Bruker Daltonik GmbH | CAMO Software AS | Catalent Pharma Solutions | Chemical Plant Equipment | Chemspec Europe Ltd | CI Precision | Dow Chemical Company Ltd | DSM Biologics | FOSS NIRSystems, Inc. | GE Analytical Instruments | GenScript USA Inc. | Gerresheimer Group | HACH LANGE GMBH | HAMAMATSU PHOTONICS EUROPE | I Holland Limited | IDBS | IONIMED Analytik GmbH | Lonza | MPI Research | Natoli Engineering Company, Inc. | PANalytical B.V. | Patheon Inc | ReAgent | Roche | Siemens AG | Sirius Analytical Instruments Ltd | TSI | Waters Corporation |
Login to access exclusive content